Mignon
Cristofoli
*a,
Jonathan
Hadgraft
b,
Majella E.
Lane
b and
Bruno C.
Sil
a
aSchool of Human Sciences, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK. E-mail: mic0501@my.londonmet.ac.uk
bSchool of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
First published on 9th April 2024
Diclofenac (DF) is well established as a topical treatment option for conditions such as osteoarthritis. In investigating novel DF ion pairs for topical delivery, studies to determine the impact of various amino acids on the distribution of DF between octanol and aqueous environments were conducted. These studies identified the amino acid L-histidine hydrochloride monohydrate (LHSS) as an ion pair candidate for diclofenac sodium (DNa). Preliminary porcine skin permeation studies indicated that the addition of LHSS to DNa solutions increased the amount of DF that permeated through porcine skin. With increasing amounts of LHSS added, greater amounts of DF precipitated out of solution. In the present work, the solubility of DNa in various solvents was assessed, with the intention of identifying solvents in which DNa was most soluble. Binary systems comprising water and selected solvents were tested for both miscibility and the solubility of DNa and LHSS. The model system selected to evaluate novel ion pair formulations using porcine skin in vitro permeation studies under finite dose (10 μL) conditions comprised Transcutol® (TC) and water. The tested formulations contained DNa at concentrations of 5, 7.5 and 10 mg mL−1. Higher LHSS concentrations were possible when the DNa concentrations were lower, and ranged from 10–25 mg mL−1. However, increasing the DNa concentration to 10 mg mL−1, without adding LHSS, resulted in a significant reduction in the amount of DF that partitioned and permeated, relative to formulations that contained either 5 mg mL−1 DNa in combination with LHSS (at 12.5 or 25 mg mL−1), or 7.5 mg mL−1 DNa together with 12.5 mg mL−1 LHSS. The current work confirms previous investigations, suggesting that the addition of LHSS to DNa in a formulation may increase the partition and permeation of DF.
Various organisations worldwide have published guidelines relating to the treatment of OA.3,4 In the UK, topical non-steroidal anti-inflammatory drugs (NSAIDs) are considered first-line pharmacological treatment options for OA, due to the adverse drug reactions associated with other options such as opioids and oral NSAIDs.5 The European Society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases have strongly recommended the use of topical NSAIDs, particularly where so-called symptomatic slow-acting drugs such as chondroitin sulfate and prescription crystalline glucosamine sulfate, in conjunction with paracetamol, have not relieved the symptoms of OA.6 In the US, the use of topical NSAIDs for the treatment of OA has been endorsed by the American College of Rheumatology in conjunction with the Arthritis Foundation7 as well as the American Academy of Orthopaedic Surgeons.8 The global organisation, Osteoarthritis Research Society International, have also strongly recommended the use of topical NSAIDs as a treatment option for OA of the knee.9 As the most prescribed NSAID worldwide,10 it is unsurprising therefore that topical formulations using diclofenac (DF) are widely recognised as effective treatment options for OA.11 Unfortunately, due to the efficacy of the barrier properties of the stratum corneum, only a small percentage of topically applied pharmaceutical salt preparations partition into the skin. Consequently, much of the applied pharmaceutical product never reaches its target site. Rational formulation design of topical DF products offers the potential for both economic savings as well as an opportunity to demonstrate commitment to reducing the environmental consequences of conscious formulation choices. This is consistent with the policies of many large pharmaceutical companies (such as Astra Zeneca,12 Novartis13 and Roche14,15) who are committed to reducing, where possible, the presence of pharmaceuticals in the environment.
Strategies to overcome the skin barrier are frequently categorised into two groups. The first comprises active or physical methods16,17 such as ionotophoresis,18–20 sonophoresis,21 microneedles,22–25 magnetophoresis26 and electroporation.27 The second consists of passive techniques that focus specifically on the formulation. Examples include increasing the thermodynamic activity of the active pharmaceutical ingredient,28–31 the inclusion of various excipients as skin penetration enhancers28,32–35 and the use of ion pairs to address ionised drug molecules.36
Previously the amino acid L-histidine hydrochloride monohydrate (LHSS) was identified as an ion pair candidate for diclofenac sodium (DNa).37 This determination resulted from studies performed to investigate the impact of LHSS on the distribution of DF between octanol and aqueous environments. Experiments comprised DNa and LHSS in various ratios, namely 1:
0.5; 1
:
1; 1
:
5, 1
:
10 and 1
:
50. The results suggested that increasing the quantity of LHSS relative to DNa, would result in an increase in the amount of DF that partitioned into an organic medium. Preliminary porcine skin permeation studies confirmed that the addition of LHSS to DNa aqueous solutions also increased the amount of DF that permeated through porcine skin. The formulations used comprised DF at 100 μg mL−1 and 350 μg mL−1. LHSS was either not included, for the purposes of a control (1
:
0) or added at 1
:
1 or 1
:
50 molar ratios. The more LHSS that was added, however, the more DF precipitated out of solution. This was particularly evident at the higher concentration of DF.37 As LHSS is only soluble in water and DNa has very low solubility in water, a binary solvent system was developed. The aims of the present study, therefore, were to build upon the previous investigations37 with two main objectives: (i) to address the issue of the solubility of both DNa and LHSS and (ii) to develop a model binary system to evaluate novel DNa
:
LHSS ion pair formulations, using porcine skin in vitro permeation studies (IVPT) under finite dose (10 μL) conditions.
![]() | (1) |
![]() | ||
Fig. 1 The results of the saturated solubility of DNa in individual solvents are plotted against their SPs (n ≥ 3; mean ± SD). The dashed red line represents the SP of DNa determined by Barra et al.44 |
As a result of the single solvent solubility studies, which indicated that DNa exhibited the highest solubility in TC, PG and DiPG, these solvents were chosen for the subsequent phase of formulation development. They are shown alongside water and DNa in Table 1 together with their CAS numbers, chemical structures, molecular weights, dielectric constant values at 25 °C and SPs. The solvents, selected primarily to maximise the solubility of DNa, are reported to function as permeation enhancers,33 and are also commonly used as excipients in topically applied pharmaceutical formulations. One such example is the inclusion of PG in the commercial formulation, Voltaren® 1% gel (GSK Consumer Health, New Jersey, USA). As such, they appear in the FDA Inactive Ingredients Database. Currently the maximum daily exposure (MDE) for TC (CAS 111-90-0) in topical applied gels is 1500 mg and the maximum potency per unit dose (MPPUD) for transdermal systems is 430 mg. PG (CAS 57-55-6) has a MDE for topically applied creams of 6113 mg and a MPPUD of 65% (w/w) for topical ointments. DiPG (CAS 25265-71-8) has a 296 mg MDE for extended-release films for transdermal use, while general transdermal systems are limited to 6 mg. No MPPUD is currently listed for DiPG contained in transdermal systems.
Compound name | CAS | Chemical structure | Molar mass (g mol−1) | Dielectric constant of solvent (ε) at 25 °C | Solubility parameter (MPa1/2) of solvents |
---|---|---|---|---|---|
DNa | 15307-79-6 |
![]() |
318.13 | n/a | n/a |
DiPG | 25265-71-8 |
![]() |
134.17 | 19.80![]() |
26.54 |
PG | 57-55-6 |
![]() |
76.09 | 28.95![]() ![]() |
28.78 |
TC | 111-90-0 |
![]() |
134.18 | 14.10![]() |
21.72 |
Water | 7732-18-5 |
![]() |
18.02 | 78.30![]() |
47.00 |
While these solvents were chosen specifically due to their efficacy as solubilisers of DNa, the work by Minghetti et al. revealed the need for caution when focusing primarily on solubility. It was ascertained that DNa was far more soluble in PG (567 ± 31 μg mL−1) and TC (660 ± 70 μg mL−1) than oleic acid (25 ± 10 μg mL−1) or water (37 ± 10 μg mL−1). Despite the application of saturated solutions, the flux from water (2.29 ± 0.37 μg cm−2 h−1) and oleic acid (1.84 ± 0.18 μg cm−2 h−1) was greater than the flux from PG (1.21 ± 0.06 μg cm−2 h−1) and TC (0.06 ± 0.01 μg cm−2 h−1).46 The study demonstrated that the assumption of equivalent thermodynamic activity for saturated solutions is negated when the activity coefficients of the solute in the solvents vary.46 This was addressed by Higuchi, who explained that a high affinity between solute and vehicle translates into low activity coefficients. This in turn results in reduced rates of partition of the solute from the vehicle into the membrane.47 Minghetti described this affinity as a very small difference between the SP of the active pharmaceutical ingredient (API) and the solvents, PG and TC, which reduced the ability of the API to partition into the membrane.46 This study indicated that a similarity in SPs could cause a reduction in the activity coefficient and therefore the thermodynamic activity of the active in the formulation. While this would suggest potential challenges for single solvent systems, or combinations of the solvents selected for maximum DNa solubility, the inclusion of water should mitigate any such concerns. The SP of water (47.00 MPa1/2) is distinct from that of PG (28.78 Mpa1/2), DiPG (26.54 Mpa1/2) and TC (21.72 Mpa1/2), and therefore should result in a higher activity coefficient, thermodynamic activity and ability to partition into the membrane. The dielectric constants of solvents and solvent systems should also be considered due to their bearing on the stability of ion pairs. In general at lower dielectric constants, the association between ion pairs increases, while the converse is true for higher dielectric constants.48,49 The three solvents TC, PG and DiPG have dielectric constants of 14.1,50 28.9551–30.2
52 and 19.8
53 respectively, at 25 °C. These values are lower than that of water which exhibits a dielectric constant of 78.3 at the same temperature.54 Thus, the addition of any of the selected solvents would result in a reduction in the dielectric constant and polarity of water alone. As the organic component of the formulation increases, the electrostatic attraction generated by the solvent system diminishes in relation to the ions. This reduction leads to decreased interference in the electrostatic attraction between the ion pairs.55
% DNa | Solvent% (v/v) | Mols LHSS/mol DNa | %DNa | Solvent% (v/v) | Mols LHSS/mol DNa | %DNa | Solvent% (v/v) | Mols LHSS/mol DNa | |||
---|---|---|---|---|---|---|---|---|---|---|---|
TC | Water | DiPG | Water | PG | Water | ||||||
LHSS solution 50 mg mL −1 | |||||||||||
0.75 | 50 | 50 | 4.71 | 1.00 | 50 | 50 | 3.53 | 0.50 | 60 | 40 | 5.65 |
0.50 | 50 | 50 | 7.06 | 0.75 | 50 | 50 | 4.71 | 0.50 | 80 | 20 | 2.83 |
0.50 | 40 | 60 | 8.48 | 0.50 | 50 | 50 | 7.06 | 0.50 | 90 | 10 | 1.41 |
0.50 | 40 | 60 | 8.48 | ||||||||
LHSS solution 25 mg mL −1 | |||||||||||
1.00 | 50 | 50 | 1.77 | 1.00 | 60 | 40 | 1.41 | 1.00 | 70 | 30 | 1.06 |
1.00 | 60 | 40 | 1.41 | 1.00 | 70 | 30 | 1.06 | 1.00 | 80 | 20 | 0.71 |
1.00 | 70 | 30 | 1.06 | 1.00 | 80 | 20 | 0.71 | 1.00 | 90 | 10 | 0.35 |
0.75 | 50 | 50 | 2.35 | 1.00 | 90 | 10 | 0.35 | 0.50 | 60 | 40 | 2.83 |
0.75 | 60 | 40 | 1.88 | 0.75 | 70 | 30 | 1.41 | 0.50 | 70 | 30 | 2.12 |
0.75 | 70 | 30 | 1.41 | 0.75 | 80 | 20 | 0.94 | 0.50 | 80 | 20 | 1.41 |
0.50 | 40 | 60 | 4.24 | 0.75 | 90 | 10 | 0.47 | 0.50 | 90 | 10 | 0.71 |
0.50 | 50 | 50 | 3.53 | 0.50 | 50 | 50 | 3.53 | ||||
0.50 | 60 | 40 | 2.83 | 0.50 | 60 | 40 | 2.83 | ||||
0.50 | 70 | 30 | 2.12 |
Amount DF partitioned and permeated | DNa 5 mg mL−1![]() ![]() |
DNa 5 mg mL−1![]() ![]() |
DNa 5 mg mL−1![]() ![]() |
---|---|---|---|
Cumulative permeation μg cm−2 at 25 h | 1.52 ± 0.32 | 1.48 ± 0.65 | 0.79 ± 0.62 |
Permeated 25 h % | 3.49 ± 0.73 | 3.47 ± 1.56 | 1.76 ± 1.37 |
Retained on the skin surface % | 65.53 ± 17.57 | 84.28 ± 2.90 | 85.02 ± 5.83 |
Retained in the membrane % | 11.00 ± 7.21 | 8.79 ± 2.05 | 7.60 ± 1.19 |
Retained in membrane plus permeated % | 14.49 ± 7.76 | 12.26 ± 3.06 | 9.36 ± 2.49 |
Recovery % | 80.02 ± 11.39 | 96.54 ± 1.81 | 94.38 ± 6.01 |
DNa![]() ![]() |
1![]() ![]() |
1![]() ![]() |
1![]() ![]() |
As mentioned previously, TC was selected due to its proficiency as a solubiliser, particularly in relation to compounds exhibiting poor water-solubility.56–58 Despite its capacity to partition into and permeate through human skin as a neat solvent59 high solubility of active ingredients in TC has not always resulted in high permeation values.46,60,61 The incorporation of water to create binary solvent systems, however, has frequently served to increase the permeation of the active compound.56,62 This has been corroborated by investigations concerning the solubility and thermodynamic activity of various low water-soluble compounds in TC, water and binary combinations thereof.40,63–67 In these studies, the compounds exhibited high solubility in TC, and had SPs that closely aligned with that of TC. A clear relationship emerged with the introduction of water, whereby an increase in the mole fraction of water corresponded to an elevated activity coefficient of the compound in the solvent system. As both the experimental and calculated SP44,45 of DNa is reported to be similar to that of TC, the addition of water increases the thermodynamic activity of the active in the formulation.67 Thus, the selection of a binary solvent system comprising a 50:
50 (v/v) ratio of TC
:
water, balances the requirement of solubility for both DNa and LHSS while addressing the issue of the thermodynamic activity of DNa in the formulation.
Recovery of DF was 94.38 ± 6.01% where no LHSS was used (5DL0), increasing to 96.54 ± 1.81% for the formulation containing 12.5 mg mL−1 LHSS (5DL12.5). Significantly less DF (80.02 ± 11.39% p < 0.05) was recovered from the final formulation, L5DL25.
Amount DF partitioned and permeated | DNa 7.5 mg mL−1![]() ![]() |
DNa 7.5 mg mL−1![]() ![]() |
---|---|---|
Cumulative permeation μg cm−2 at 25 h | 1.49 ± 0.76 | 0.22 ± 0.19 |
Permeated 25 h % | 2.24 ± 1.15 | 0.35 ± 0.30 |
Retained on the skin surface % | 88.18 ± 4.41 | 94.64 ± 5.66 |
Retained in the membrane % | 8.14 ± 2.24 | 3.95 ± 0.12 |
Retained in membrane plus permeated % | 10.38 ± 2.49 | 4.30 ± 0.42 |
Recovery % | 98.56 ± 4.89 | 98.94 ± 6.08 |
DNa![]() ![]() |
1![]() ![]() |
1![]() ![]() |
Although one of the previous formulations tested (5DL12.5 shown in Table 3) contained an equivalent quantity of LHSS (12.5 mg mL−1 LHSS), the increase in the concentration of DNa from 5–7.5 mg mL−1, resulted in a change to the DNa:
LHSS molar ratio. Previously (5DL12.5) this ratio was 1
:
3.5, reducing to 1
:
2.35 (7.5DL12.5), as a result of the increase in DNa concentration. These changes appeared to have no significant impact on the cumulative permeation of DF from the 7.5DL12.5 formulation (1.49 ± 0.76 μg cm−2) relative to the 5DL12.5 experiment (1.48 ± 0.65 μg cm−2, p > 0.05). When viewed as a percentage of the DF applied, the amount reduced from 3.47 ± 1.56% (5DL12.5) to 2.24 ± 1.15% (7.5DL12.5), however this was not considered statistically significant (p > 0.05). When considering the quantity of DF in the membrane, the addition of LHSS in the current experiment (7.5 mg mL−1 DNa) resulted in a significantly higher percentage being extracted (8.14 ± 2.24%) when compared to the control (3.95 ± 0.12%, p < 0.05). This remained consistent when the percentage of DF that permeated was added to that extracted from the membrane, with values of 10.38 ± 2.49% for the LHSS formulation and 4.30 ± 0.42% for the control (p < 0.05).
A comparison of the percentage of DF extracted from the membrane for the 5DL12.5 samples (8.79 ± 2.05%) with the results of the 7.5DL12.5 samples (8.14 ± 2.24%), showed no significant differences (p > 0.05). Moreover, the combination of the amount of DF that permeated with that extracted from the membrane amounted to 12.26 ± 3.06% for the 5DL12.5 formulation, which was comparable to 10.38 ± 2.29% for the 7.5DL12.5 preparation (p > 0.05). Recovery of DF was approximately 98% for both the 7.5 mg mL−1 DNa formulation containing LHSS as well as the control. This was consistent with the range recommended by the OECD guidelines.68
Amount DF partitioned and permeated | DNa 10 mg mL−1![]() ![]() |
DNa 10 mg mL−1![]() ![]() |
---|---|---|
Cumulative permeation μg cm−2 at 25 h | 1.01 ± 0.91 | 0.36 ± 0.44 |
Permeated 25 h % | 1.10 ± 0.98 | 0.41 ± 0.49 |
Retained on the skin surface % | 93.55 ± 1.90 | 93.43 ± 5.49 |
Retained in the membrane % | 4.31 ± 1.34 | 4.39 ± 0.95 |
Retained in membrane plus permeated % | 5.41 ± 2.21 | 4.80 ± 1.08 |
Recovery % | 98.96 ± 0.86 | 98.23 ± 5.13 |
DNa![]() ![]() |
1![]() ![]() |
1![]() ![]() |
Furthermore, the percentage and actual amounts (μg cm−2) of DF that permeated from 10DL10 and 10DL0 were comparable to both 7.5 mg DNa formulations as well as the 5 mg DNa formulation control formulations (p > 0.05). However, percentages of DF that permeated from the 5 mg mL−1 formulations, 5DL12.5 (3.47 ± 1.56%) and 5DL25 (3.49 ± 0.73%), were significantly greater than the 1.10 ± 0.98% that permeated from 10DL10 (p < 0.05).
Analysis of the percentage of DF retained within the skin for the 10 mg mL−1 DNa formulations, revealed no significant differences between 10DL10 (4.31 ± 1.34%) and 10DL0 (4.39 ± 0.95%, p > 0.05). Furthermore, the combined values of DF extracted from the membrane and permeating, amounted to 5.41 ± 2.21% (10DL10) and 4.80 ± 1.08% (10DL0), were not significantly different (p > 0.05). This suggests that the molar ratio of DNa:
LHSS (1
:
1.41), did not impact either partition into the skin or permeation in this solvent system. Comparisons of the amounts of DF retained in the membrane for 7.5 and 10 mg mL−1 DNa formulations did, however, reveal significant differences when LHSS was included. The reduction of LHSS (12.5–10 mg mL−1), while simultaneously varying the solvent ratio (TC
:
water from 50
:
50–60
:
40), caused a significant decrease in the percentage of DF retained in the membrane. This amount reduced from 8.14 ± 2.24% (7.5DL12.5) to 4.31 ± 1.34% (10DL10) despite the increase in DNa concentration (7.5–10 mg mL−1, p < 0.05). This was not the case, however in relation to the 7.5DL0, where the DF retained in the membrane was comparable to that of the 10DL10 formulation (p > 0.05). As mentioned previously, this could indicate that the molar quantity of LHSS was not high enough relative to that of DNa, to result in an increase in penetration of the active. The total percentage of DF that partitioned and permeated reflected a similar pattern, significantly decreasing from 10.38 ± 2.49% (7.5DL12.5) to 5.41 ± 2.21% (10DL10) (p < 0.05). There was no significant difference in the percentages that partitioned and permeated from the 7.5DL0 (4.30 ± 0.42%) and 10DL10 (5.41 ± 2.21%) formulations (p > 0.05).
Differences in the amounts of DF retained in the membrane between the two 5 mg mL−1 preparations and the 10 mg mL−1 formulation containing LHSS, were also statistically different (p < 0.05). Notwithstanding the increase in the concentration of DNa (5–10 mg mL−1), the quantity of DF extracted from the membrane reduced from 8.79 ± 2.05% (5DL12.5) and 11.00 ± 7.21% (5DL25) to 4.31 ± 1.34% for the 10DL10 formulation. When the amount of DF permeating was added to that recovered from the skin, the results followed the same pattern. Values reduced from 12.26 ± 3.06% (5DL12.5) and 14.49 ± 7.76% (5DL25) when the concentration of DNa applied was 5 mg mL−1 to 5.41 ± 2.21% (10DL10) when the concentration of DNa increased to 10 mg mL−1 (p < 0.05). Values of DF for 5DL0 (9.35 ± 2.49%) and 10DL10 (5.41 ± 2.21%) were comparable (p > 0.05).
The observed changes can be partially attributed to the adjustment of the TC:
water solvent ratio from 50
:
50 to 60
:
40 (v/v). This modification directly impacts the SP of the solvent system,65,66 reducing it from 34.36 to 31.83 MPa1/2, bringing it closer to the SPs of TC and DNa. The thermodynamic consequences of increasing the TC fraction in binary TC
:
water systems, where the permeant is sparingly soluble in water, but freely soluble in TC, were investigated using paracetamol,69 DNa67,69 and various other active ingredients.40,63–66 It was shown that increasing TC relative to water decreased the thermodynamic activity of the active ingredients within the solvent systems. This effect was demonstrated by Bialik et al. with IVPT using ibuprofen.62 Due to its low solubility in water (0.021 mg mL−1) relative to TC (400 mg mL−1),56 ibuprofen permeation decreased with increasing TC concentration, due to the alteration of the permeant's thermodynamic activity in the vehicle.62
Apart from the alteration in solvent ratio, the reduction in the DNa:
LHSS molar ratio to (1
:
1.41) could have contributed to a decrease in DF partitioning and permeation. This may indicate that a minimum amount of LHSS is required to achieve any increased partition and permeation results. Prior studies have indicated a correlation between DF partitioning and increased LHSS counter ion concentration.37
Finally, as shown in Table 5, recovery of the DF applied exceeded 98% for both the 10DL10 and the control sample sets, satisfying the guidelines set out by the OECD.68
The selection of TC, a solvent with a SP similar to that reported for DNa, resulted in a large increase in the solubility of the active when compared to our previous work. Challenges associated with this choice, such as a reduction in the activity coefficient of DNa in the solvent system and its ability to partition out of the formulation and into the membrane, were addressed by the inclusion of water. The effect of reducing the water content was demonstrated by the alteration of the TC:
water ratio from 50
:
50 to 60
:
40 (v/v). Although the increase in TC enabled the DNa concentration to be doubled (5–10 mg mL−1), this had no significant effect on the actual amount of DF partitioning and permeating from the 10DL0 system, relative to any of the other control samples. Furthermore, the reduction in the dielectric constant of the solvent system attributable to the increase in the TC fraction, was not able to offset the drop in the quantity of LHSS from 25 mg mL−1 and 12.5 mg mL−1 to 10 mg mL−1. This was evidenced by the significant reduction the amount of DF partitioning and permeating from the 10DL0 formulation relative to the 5DL12.5, 5DL25 and 7.5DL12.5 samples.
The studies showed that while the inclusion of LHSS at 5 mg mL−1 increased the partition and permeation of DF by approximately 30% (5DL12.5) and 55% (5DL25) relative to the control; this was not statistically significant. However, when the concentration of DNa was increased to 7.5 mg mL−1 (7.5DL12.5), the inclusion of LHSS significantly enhanced the amount of DF that partitioned and permeated (approximately 145%), when compared to the control formulation. The increase in the amount of DNa from 5–7.5 mg mL−1 had no significant effect on the partition and permeation of DF, when the quantity of LHSS remained constant at 12.5 mg mL−1.
In accordance with our previous investigations, the current work suggests that the inclusion of LHSS with DNa in a formulation may increase the partition and permeation of DF. This represents a further step in the development of an ion pair formulation where less DNa may be required within the preparation to achieve a therapeutic result. In continuing this process, the solubility of the active and the counter ion require further consideration, particularly in relation to the ratio in which they are most effective. Additionally, the importance of the activity coefficient of the active in the formulation should be balanced with the potential to stabilise the ion pairs, by increasing the use of solvents with a lower dielectric constant than water. Further work has already commenced exploring the implications of substituting TC with an alternative solvent, DiPG, as the DNa-solubiliser. This substitution should enable the impact of a solvent change on IVPT results to be determined. Additional investigations will incorporate more than one solvent into the DNa-solubilising fraction. These ternary systems will be tested via IVPT to further optimize the ion pair formulation.
This journal is © The Royal Society of Chemistry 2024 |